Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Neoplasms by Site 1Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bronchial Neoplasms 1

Interventions

Pemetrexed 5Carboplatin 5Paclitaxel 3osimertinib 2Gemcitabine 2pralsetinib 1pembrolizumab 1patritumab 1napabucasin 1atezolizumab 1alectinib 1Vinorelbine 1Patient Reported Outcome Measures 1Nivolumab 1Metformin 1Indocyanine Green 1Erlotinib Hydrochloride 1Cisplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thoracic Neoplasms × napabucasin × Clear all
NCT02826161 2023-11-15

CanStem43L

Sumitomo Pharma America, Inc.

Phase 3 Terminated
4 enrolled 6 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡